Belvarafenib

Phase 2Small molecule

Roche

Belvarafenib is one of 80 small molecule programs targeting Primary Brain Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Brain TumorRecruiting

Solid TumorActive, not recruiting

MelanomaRecruiting

Primary Brain TumorPhase 2

Recruiting

Solid TumorPhase 2

Active, not recruiting

MelanomaPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Fludara

Sanofi

Preclinical

1 3

Belvarafenib

Roche

Phase 2

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 8

Soc

Pfizer

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

Tulmimetostat

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Melanoma

NCT04835805

Q4 2029

Phase 2Recruiting

Primary Brain Tumor

NCT07688356

Q1 2030

Phase 2Recruiting

Melanoma

NCT07449754

Q3 2032

Phase 2Active, not recruiting

Solid Tumor

NCT04589845

Clinical

Trials by Indication[1]

Melanoma2 trials

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT07449754·45 enrolled

A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy

Active, not recruiting· Roche logo

Roche·Phase 1·NCT04835805·65 enrolled

Solid Tumor1 trial

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruiting· Roche logo

Roche·Phase 2·NCT04589845·920 enrolled

Primary Brain Tumor1 trial

An Exploratory Phase 2 Study for Evaluating CNS Efficacy of Belvarafenib in Patients With BRAF-Altered Solid Tumors

Recruiting·SSamsung Medical Center·Phase 2·NCT07688356·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Belvarafenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Belvarafenib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Belvarafenib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

Belvarafenib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Q1 2030

Q3 2032

Trials by Indication[1]

Melanoma2 trials

Solid Tumor1 trial

Primary Brain Tumor1 trial

References

Drug Info

Quick Facts

Related News